Organon, Dermavant
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion
Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million, along with up to $1.025 billion in milestone payments.
Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced ...
Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...
GlobalData on MSN7d
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiaryAs part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
Women’s health specialist Organon has entered into a definitive agreement to acquire Dermavant Sciences, a Roivant company.
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...
Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...
Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback